Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Idasanutlin ADME and Bioavailability Study
NCT02828930Phase 1Completed
- Sponsor
- Roche
- Start
- Sep 2016
- Primary completion
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of idasanutlin in solid tumor, sponsored by Roche. Primary endpoints: Time to Reach Maximum Observed Plasma Concentration, Maximum Observed Plasma Concentration and 10 more. Started Sep 2016; status: completed.
02
Drugs
idasanutlin
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02828930.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02828930.